PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Fluconazole (Primary) ; Posaconazole (Primary) ; Posaconazole (Primary)
- Indications Aspergillosis; Mycoses
- Focus Therapeutic Use
- Acronyms PTX3AML
- 20 Dec 2022 Planned End Date changed from 31 Jul 2022 to 30 Nov 2025.
- 20 Dec 2022 Planned primary completion date changed from 31 Jul 2022 to 30 Nov 2025.
- 14 Feb 2019 Status changed from not yet recruiting to recruiting.